Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2689
Título : Glutamyl aminopeptidase in microvesicular and exosomal fractions of urine is related with renal dysfunction in cisplatin-treated rats
Autor : Quesada, Andrés
Segarra, Ana Belén
Montoro-Molina, Sebastián
de Gracia, María Del Carmen
Osuna, Antonio
O'Valle, Francisco
Gómez-Guzmán, Manuel
Vargas, Félix
Wangensteen, Rosemary
Filiación: [Quesada,A; de Gracia,MC; Osuna,A] Unidad de Nefrología, Hospital Virgen de las Nieves, FIBAO, Granada, Spain. [Segarra,AB; Montoro-Molina,S; Gómez-Guzmán,M; Wangensteen,R] Área de Fisiología, Departamento de Ciencias de la Salud, Universidad de Jaén, Jaén, Spain. [O’Valle,F] Departamento de Anatomía Patológica, IBIMER, Universidad de Granada, Granada, Spain. [Vargas,F] Departamento de Fisiología, Facultad de Medicina, Universidad de Granada, Granada, Spain.
Palabras clave : Animales
Antígenos CD13
Peso corporal
Centrifugación
Cisplatino
Creatinina
Técnicas para inmunoenzimas
Espacio extracelular
Glutamil aminopeptidasa
Pruebas de función renal
Neoplasias
Ratas
Aumento de peso
MeSH: Medical Subject Headings::Organisms::Eukaryota::Animals
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Exopeptidases::Aminopeptidases::Antigens, CD13
Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Centrifugation
Medical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Chlorine Compounds::Cisplatin
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Imidazoles::Creatinine
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunoassay::Immunoenzyme Techniques
Medical Subject Headings::Anatomy::Cells::Cellular Structures::Extracellular Space
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Exopeptidases::Aminopeptidases::Glutamyl Aminopeptidase
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunoassay::Immunoblotting
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Urological::Kidney Function Tests
Medical Subject Headings::Diseases::Neoplasms
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Rats
Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Physiological Processes::Growth and Development::Growth::Body Size::Body Weight::Body Weight Changes::Weight Gain
Fecha de publicación : 11-Apr-2017
Editorial : Public Library of Science
Cita Bibliográfica: Quesada A, Segarra AB, Montoro-Molina S, de Gracia MD, Osuna A, O'Valle F, et al. Glutamyl aminopeptidase in microvesicular and exosomal fractions of urine is related with renal dysfunction in cisplatin-treated rats.PLoS One. 2017;12(4):e0175462.
Abstract: PURPOSE: The aim of this work was to investigate if the content of glutamyl aminopeptidase (GluAp) in microvesicular and exosomal fractions of urine is related with renal dysfunction in cisplatin-treated rats. METHODS: Urine samples were collected 24 hours after injection of cisplatin (7 mg/kg, n = 10) or saline serum (n = 10), and they were subjected to differential centrifugation at 1.000, 17.000 and 200.000 g to obtain microvesicular and exosomal fractions. GluAp was measured with a commercial ELISA kit in both fractions. Serum creatinine (SCr) and body weight were measured 15 days after treatment. We analyzed if early excretion of GluAp in microsomal and exosomal fractions was correlated with final SCr and body weight increase. In a second experiment, enzymatic activities of GluAp and alanyl aminopeptidase (AlaAp) in urine, microvesicular and exosomal fractions were measured three days after injection. We analyzed the correlation of both markers with SCr determined at this point. Finally, we studied the expression of GluAp and extracellular vesicles markers Alix and tumor susceptibility gene (TSG101) in both fractions by immunoblotting. RESULTS: GluAp excretion was increased in all fractions of urine after cisplatin treatment, even if data were normalized per mg of creatinine, per body weight or per total protein content of each fraction. We found significant predictive correlations with SCr concentration, and inverse correlations with body weight increase determined 15 days later. Three days after injection, aminopeptidasic activities were markedly increased in all fractions of urine in cisplatin-treated rats. The highest correlation coefficient with SCr was found for GluAp in microvesicular fraction. Increase of GluAp in microvesicular and exosomal fractions from cisplatin-treated rats was confirmed by immunoblotting. Alix and TSG101 showed different patterns of expression in each fraction. CONCLUSIONS: Determination of GluAp content or its enzymatic activity in microvesicular and exosomal fractions of urine is an early and predictive biomarker of renal dysfunction in cisplatin-induced nephrotoxicity. Measurement of GluAp in these fractions can serve to detect proximal tubular damage independently of glomerular filtration status.
URI: http://hdl.handle.net/10668/2689
Versión del editor : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175462
DOI: 10.1371/journal.pone.0175462
ISSN : 1932-6203 (Online)
Appears in Collections:01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
Quesada_GlutamylAminopeptidase.pdfArtículo publicado897,88 kBAdobe PDFView/Open
Quesada_GlutamylAminopeptidaseS1File.xlsMaterial suplementario77,5 kBMicrosoft ExcelView/Open


This item is licensed under a Creative Commons License Creative Commons